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ABSTRACT  
In skeletal muscle, excitation-contraction coupling is the process whereby the voltage-gated 
dihydropyridine receptor (DHPR) located on the transverse tubules activates calcium release 
from the sarcoplasmic reticulum by activating ryanodine receptor (RyR1) Ca2+ channels 
located on the terminal cisternae. This subcellular membrane specialization is necessary for 
proper intracellular signalling and any alterations in its architecture may lead to 
neuromuscular disorders. In this study we present evidence that patients with recessive RYR1-
related congenital myopathies due to primary RyR1 deficiency also exhibit down-regulation 
of the alfa 1 subunit of the DHPR and show disruption of the spatial organization of the 
excitation-contraction coupling machinery. We created a cellular RyR1 knock-down model 
using immortalized human myoblasts transfected with RyR1 siRNA and confirm that 
knocking down RyR1 concomitantly down-regulates not only the DHPR but also the 
expression of other proteins involved in excitation-contraction coupling. Unexpectedly, this 
was paralleled by the up-regulation of inositol-1,4,5-triphosphate receptors; functionally 
however, up-regulation of the latter Ca2+ channels did not compensate for the lack of RyR1-
mediated Ca2+ release. These results indicate that in some patients, RyR1 deficiency 
concomitantly alters the expression pattern of several proteins involved in calcium 
homeostasis and that this may influence the manifestation of these diseases.  
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Introduction  
The precise regulation of intracellular calcium homeostasis is critical for normal skeletal 
muscle development and function. Excitation-contraction (E-C) coupling requires the correct 
assembly, distribution and interaction of a number of proteins found in the sarcoplasmic 
reticulum (SR), the organelle of striated muscle dedicated to calcium homeostasis. Two key 
elements involved in calcium release are the voltage-gated dihydropyridine receptor (DHPR, 
MIM# 114208), located on the transverse tubules, and the ryanodine receptor (RyR1, MIM# 
180901), the principal calcium release channel of skeletal muscle situated in the terminal 
cisternae of the SR (Nakai et al., 1996). The predicted structure of the RyR1 suggests that the 
calcium release pore is located in the C-terminal domain of the protein, whereas the N-
terminal domain constitutes the foot structure that interacts with DHPR (Ramachandran et al., 
2009; VanPetegem, 2012; Dulhunty and Pouliquin, 2003). The direct physical interaction 
between DHPR and RyR1 is essential for skeletal muscle E-C coupling and any alterations in 
the subcellular distribution of proteins or membranes involved E-C coupling can lead to 
impaired muscle function (Pan et al., 2002; Oddoux et al., 2009).  
 Disturbance of calcium homeostasis due to defects in RyR1 is the underlying feature 
of the malignant hyperthermia susceptibility (MHS, MIM# 145600) trait, a pharmacogenetic 
reaction to volatile anaesthetics and muscle relaxants, and a wide range of congenital 
myopathy phenotypes, including dominantly inherited Central Core Disease (CCD, MIM# 
117000) and recessively inherited Multi-minicore Disease (MmD, MIM# 255320) with or 
without opthalmoplegia (Jungbluth et al., 2002; Jungbluth et al., 2005; Quane et al., 1993; 
Zhou et al., 2006; Zhou et al., 2007), subgroups of Centronuclear Myopathy (CNM), 
Congenital Fibre Type Disproportion (CFTD) and the King-Denborough Syndrome (KDS) 
(Clarke et al., 2010; Dowling et al., 2011; Wilmshurst et al., 2010; Jungbluth et al., 2007). 
Whilst dominantly inherited RYR1-related congenital myopathies have been extensively 
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studied and are usually attributed to RyR1 channels that are either “leaky” or show impaired 
calcium conductance (Treves et al., 2008; Dirksen and Avila, 2002), the pathogenesis of 
recessively inherited RYR1-related myopathies is not well understood, though a decrease in 
RyR1 protein content has been reported in muscle biopsies from some patients (Zhou et al., 
2007; Wilmhurst et al., 2010). Besides mutations in the RYR1, substitutions in other genes 
linked to neuromuscular disorders, encoding proteins involved in E-C coupling have so far 
been reported only for CACNA1, the gene encoding the alfa 1 subunit of the DHPR (Cav1.1) 
in patients with malignant hyperthermia (Pirone et al., 2010; Toppin et al., 2010; Monnier et 
al., 1997). We recently reported that a patient with periodic paralysis who harboured 
recessively inherited RYR1-mutations (Zhou et al., 2010) with no CACNA1S mutation, had a 
marked reduction of RyR1 protein and a disruption of RyR1/Cav1.1 co-localization, 
indicating potential secondary effects of certain RYR1 mutations on key proteins of the E-C 
coupling machinery.  
 In the present investigation we extended these findings and report abnormal 
expression and distribution of Cav1.1 in muscle biopsies from a number of patients with 
recessive RYR1 mutations with reduced RyR1 content. Mimicking RyR1 depletion in human 
myotubes using a RYR1 siRNA knock down approach caused a decrease in Cav1.1 with a 
concomitant up-regulation of inositol-1,4,5-trisphosphate receptors (IP3R, MIM# 147265). 
These results provide new insights into the pathogenesis of recessive RYR1-related 
myopathies with primary RyR1 deficiency.  
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Materials and Methods 
Muscle Biopsies 
Studies on muscle biopsies from patients were approved by the author’s Institutional Ethical 
Committee and conducted under the Declaration of Helsinki. Patients were encoded to 
protect their confidentiality, and written informed consent obtained. Routine 
histopathological studies were performed according to standard procedures. All patients 
presented in this study have a clear clinical and histological diagnosis of a congenital 
myopathy, and were molecularly diagnosed as having RYR1 mutations. Control muscle 
biopsies were from donors with no neuromuscular diseases.  RNA samples were studied in 19 
patients and 9 controls; immunohistochemical studies were performed in 4 patients and 3 
controls; Western blot studies were performed in 2 patients and 3 controls. 
Molecular Genetics  
The genetic information of all patients was taken from the genetic reports. The RYR1 
nucleotide numbering is based on transcript variant NM_00540.2, where the nucleotide 
numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence, according to journal guidelines 
(www.hgvs.org/mutnomen). The initiation codon is codon 1. The variants reported have been 
submitted to the Leiden RYR1 locus specific database (http://www.lovd.nl/RYR1). 
Immortalization and Culture of Skeletal Muscle Cell Line 
Human satellite cells were derived from the skeletal muscle biopsy of a 19-year-old female 
donor with no neuromuscular disorder. Skeletal muscle cell line immortalization was 
performed as previously described (Zhu et al., 2007; Mamchaoui et al., 2011). Briefly, 
cultured cells were double transfected by recombinant retroviruses containing the telomerase 
(hTERT) cDNA and Cdk4 cDNA, followed by clonal selection of myogenic lines. 
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Immortalized myoblasts were maintained in skeletal muscle cell growth medium (PromoCell) 
in low oxygen atmosphere (5% O2 and 5% CO2) at 37ºC. 
Immunofluorescence 
All cryosections from muscle biopsies were cut at a thickness of 8 µm for 
immunohistochemistry. Sections were incubated with primary antibodies at room temperature 
for one hour, washed in 0.1M phosphate buffered saline pH 7.2 (PBS) and incubated with 
secondary antibody conjugated to Alexa 488 and biotinylated secondary antibody for one 
hour at room temperature, followed by thorough rinsing in PBS. After washing, muscle 
sections were incubated with streptavidin conjugated to Alexa 594 for 15 minutes at room 
temperature then washed and mounted using Hydromount mounting medium (National 
Diagnostics). Images were digitally captured using Metamorph software. For 
immunofluorescence on myotubes, glass coverslip grown cells were fixed for 30 minutes in 
3.7% paraformaldehyde in PBS; cells were rinsed with PBS and permeabilized with 1% 
Triton X-100 in PBS for 30 minutes. After incubation with blocking buffer (1% blocking 
buffer, Roche, in PBS) for 60 min at room temperature, slides were processed as described 
above. The primary antibodies used for immunohistochemistry were mouse anti-RyR1 
monoclonal antibody (1:500, Abcam), goat anti- Cav1.1 polyclonal antibody (1:200, Santa 
Cruz) and rabbit anti-ß-tubulin (1:20, Santa Cruz).  
cDNA Synthesis and Quantitative Real-time PCR 
Total RNA was extracted from muscle biopsies using the RNeasy kit (Qiagen); 500 ng of 
each RNA sample was used for first-strand cDNA synthesis with Superscript III reverse 
transcription kit (Invitrogen). Quantitative real-time PCR products of RYR1, CACNA1S and 
DES were amplified with the TaqMan universal PCR Master Mix (Applied Biosystems). 
Samples were incubated in a 25µl reaction mix according to manufacturer’s instructions. 
Quantitative real-time PCR was performed using Applied Biosystem fast 7500 Real Time 
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PCR System using the recommended program: activation at 50ºC for 2 min and 95ºC for 10 
min, 40 cycles of 95ºC for 15sec and 60ºC for 1 min. Quantification was based on the 
comparative ∆∆Ct method. One of the samples treated with negative control siRNA was used 
to calibrate the data and to analyse results. For ITPR1, ITPR2 and ITPR3 quantitative real-
time PCR samples were amplified with MESA Blue qPCR kit (Eurogentec). Gene specific 
qPCR primers, including ITPR1, ITPR2, ITPR3, GAPDH and DES, were commercially 
available from Qiagen. Samples were incubated in a 25µl reaction mix according to 
manufacturer’s instructions.  Quantitative real-time PCR was performed using Applied 
Biosystem fast 7500 Real Time PCR System using the recommended program: activation at 
95ºC for 5min, 40 cycles of 95ºC for 3sec and 60ºC for 1min. Quantification was based on 
concurrent standard curves produced from serial dilutions of control cDNA from untreated 
cultured myotubes. DES and GAPDH were used as internal reference genes. The expression 
of ITPRs in cultured myotubes or muscle biopsies were normalized by DES or GAPDH, and 
calibrated by taking the ratio of one of the control samples as 1.0. Total RNA was extracted 
from human myotubes using Trizol (Invitrogen) and cDNA synthesized with the High 
Capacity cDNA synthesis kit from Applied Biosystem and the following primers: MYH 1- 
Myosin heavy chain: Forward : 5’ GGG AGA CCT AAA ATT GGC TCA A  3’ Reverse: 5’ 
TTG CAG ACC GCT CAT TTC AAA 3’ TNNT1 – Troponin T1 : Forward: 5’ TGA TCC 
CGC CAA AGA TCC C 3’ Reverse: 5’ TCT TCC GCT GCT CGA AAT GTA 3’ DAG1 – 
Dystroglycan 1 : Forward: 5’ AGC AAA GGA TTG ACC TCC TGC 3’ Reverse: 5’ CCA 
CCG GCA CTA ATT TCA TGT T 3’ Desmin : Forward : 5’ AAC CAG GAG TTT CTG 
ACC ACG  3’ Reverse: 5’ TTG AGC CGG TTC ACT TCG G 3’ GAPDH: Forward : 5’ 
CTG GGC TAC ACT GAG CAC C 3’ Reverse: 5’AAG TGG TCG TTG AGG GCA ATG 3’. 
As well as the ITPR primers described above. Transcript levels were normalized to GAPDH 
expression levels. 
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Western Blotting 
Total protein was extracted from cells lysates or frozen skeletal muscle sections in sampling 
buffer consisting of 75 mM Tris-HCl, 1% SDS and cocktail of protease inhibitor (Roche). 
Protein concentration was quantified by the BCA protein assay kit (Pierce). Thirty 
micrograms of proteins were loaded and separated using NuPAGE Pre-cast gels (3-8% Tris-
acetate, Invitrogen) and then transferred electrophoretically to nitrocellulose membrane (GE 
Healthcare). The membrane was blocked with 5% goat serum (Sigma) in phosphate buffered 
saline buffer with 0.5% Tween-20 (PBS-T) and then probed with primary antibodies at room 
temperature for 1 hour or 4º C overnight. After washing in PBS-T, membranes were 
incubated with HRP-anti-mouse or HRP-anti-rabbit IgG (the Jackson Laboratory, 1:50,000) 
for one hour at room temperature. Immunoreactivity was visualized using enhanced 
chemiluminescence detection kit (GE Healthcare). Semi-quantification of the bands was 
performed by densitometric analysis and data was processed using the Image J software.  
The primary antibodies used in this study include mouse monoclonal anti-RyR1 (Abcam, 
1:2,500), rabbit anti- Cav1.1 (Santa Cruz, 1:1,000), mouse monoclonal -anti-desmin (DAKO, 
1:2,000), mouse monoclonal anti- IP3R III (BD, 1:1,000), mouse monoclonal anti-SERCA2 
antibody (Abcam, 1:1,000), mouse monoclonal anti α-actinin 2 (Sigma, 1:20,000) and mouse 
monoclonal anti-β-tubulin (Sigma, 1:4,000).  
RYR1 Knock-down by siRNA  
Immortalized myoblasts obtained as described above (Immortalization and culture human 
skeletal muscle cell line) were seeded on 30 mm diameter plates at a density of 5~8 × 105 
cells per well in order to be confluent by the next day. RYR1 siRNA (Santa Cruz 
Biotechnology) was transfected using lipofectamine 2000 in OptiMEM medium following 
the manufacturer’s recommendations (Invitrogen). A series of concentrations [10nM, 30nM 
and 50nM] of siRNA were tested and cells treated with the same concentrations of negative 
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siRNA were used as control. The transfection medium was changed to differentiation 
medium (PromoCell) 6 hours post transfection and changed thereafter every 2 days; cells 
visibly started to fuse 4-5 days after transfection/differentiation, and myotubes were collected 
at day 7. 
Intracellular Calcium Measurements 
Myotubes, mock transfected or transfected with 50nM siRNA, were either untreated or 
treated with 1 µM Xestsospongin C (Sigma chemicals) for 40 minutes during fura-2 (final 
concentration was 5 µM) loading. Cells were rinsed one time with Krebs-Ringer and then 
coverslips were mounted onto a 37ºC thermostated chamber which was continuously 
perfused with Krebs Ringer medium; individual cells were stimulated with the indicated 
agonists (60 mM KCl, 600 µM 4-chloro-m-cresol, 100 µM ATP) made up in Krebs Ringer 
containing no added Ca2+ plus 100 µM La3+ in order to monitor changes in the cytoplasmic 
calcium concentration due to release from intracellular stores, by means of a 12-way 100mm 
diameter quartz micromanifold computer-controlled microperfuser (ALA Scientific 
Instruments), as previously described (Ducreux et al., 2004). On-line measurements were 
recorded using a fluorescent Axiovert S100 TV inverted microscope (Carl Zeiss GmbH, Jena, 
Germany) equipped with a 20× water-immersion FLUAR objective (0.17 NA), filters (BP 
340/380, FT 425, BP 500/530) and attached to a Cascade 125+ CCD camera. Changes in the 
free cytosolic calcium concentration were analysed using MetaMorph (molecular devices) 
imaging system and the average pixel value for each cell was measured as previously 
described (Ducreux et al., 2004; Treves et al., 2010).    
 Statistical Analysis 
Statistical analysis was performed using the Student’s t test for comparison of two samples or 
the ANOVA test for comparison of multiple data, followed by the Bonferroni’s post hoc test. 
GraphPad Prism 5 and Origin softwares were used for statistical analysis and graph design. 
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Results 
RyR1 and DHPR Expression and Distribution in Skeletal Muscle Biopsies from Patients 
Carrying RYR1 Mutations  
 Fig. 1 shows immunohistochemical staining on skeletal muscle biopsies from three 
patients carrying recessive RYR1 mutations, one patient carrying a dominant RYR1 mutation 
and one control individual. A summary of the clinical and histopathological features and 
genetic details of the patients is given in Supplementary Table S1. Patient 1 carried the 
heterozygous mutations p.R109W+p.M485V in one allele and the missense plus nonsense 
mutations p.D708N+p.R2241X in the other allele; patient 2 carried the heterozygous 
p.E879K mutation in one allele and the splice site mutation c.3381+1G>A in the other allele. 
Patient 3 carried the dominant RYR1 mutation p.G4638D and patient 4 carried the 
homozygous missense mutation p.R3772Q. No additional mutations were found after 
screening the entire RYR1 coding region of each patient. Biopsies from patients 3 and 4, 
where histopathology showed typical central or eccentric cores on NADH staining, showed 
the same patterns of distribution of DHPR and RyR1 in a rim around the core area (Fig. 1). 
On the other hand, a segregated distribution of RyR1 and DHPR was observed in muscle 
sections from patients 1 and 2, in whom histopathology showed the characteristic multi-mini 
cores on NADH staining, there was distinct aggregation of the DHPR in some of the muscle 
fibres in associated with  reduction of RyR1 staining.  
 
RYR1 But Not CACNA1S Transcript Is Reduced in Skeletal Muscle from Patients 
Carrying Recessive RYR1 Mutations  
To investigate changes in RYR1 expression at the transcriptional level, we performed 
quantitative real-time PCR of RYR1 in patient’s muscle biopsies, using DES as the skeletal 
muscle specific reference gene. RNA samples extracted from muscle biopsies of 19 patients 
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with confirmed RYR1 mutations were collected for this study. Patients were arranged into 
three groups according to the types of mutations. RYR1-AD group consisted of 6 patients 
carrying dominant RYR1 mutations; RYR1-R1 group included 4 patients with recessive 
homozygous or compound heterozygous missense mutations; and RYR1-R2 group included 9 
patients carrying heterozygous recessive mutations in which one allele contained a missense 
mutation, and the other a loss of function mutation. We also included biopsies from 9 normal 
control individuals in the control group. The relative expression of RYR1 was 0.89±0.07 in 
the control group, 0.83±0.10 in the RYR1-AD group, 0.61±0.07 in the RYR1-R1 group and 
0.57±0.06 in the RYR1-R2 group (Fig. 2A). Significant reduction of RYR1 mRNA transcripts 
was observed in RYR1-R1 and RYR1-R2 groups, where patients were affected by recessive 
mutations on both alleles, compared to control group (P=0.0035 between RYR1-R2 and 
control; P=0.044 between RYR1-R1 and control). No difference was observed in patients 
carrying dominant RYR1 mutations (RYR1-AD) compared with control group. CACNA1S 
mRNA was also measured by quantitative real-time but no significant difference was 
observed in its transcription level in muscle biopsies between mutation groups and controls 
(Fig. 2B).  
 We further investigated the effects of RyR1 depletion by performing RyR1 
knockdown experiments on an immortalized human muscle cell line, using RYR1 siRNA. 
Seven days after transfection and differentiation, once visible multinucleated myotubes 
appeared, RYR1 mRNA was quantified by real-time PCR. As shown in Fig. 3A the RYR1 
transcript was reduced in a siRNA concentration- dependent manner. The relative expression 
of RYR1 mRNA was: 0.47±0.09 for the 10 nM siRYR1 group; 0.31± 0.03 for the 30 nM 
siRYR1 group and 0.23±0.03 for the 50 nM siRYR1 group compared to the control group 
(1.0±0.0). In the same samples the relative expression of CACNA1S (Fig. 3B) and DES (Fig. 
3C) were not significantly changed.  
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Down-regulation of RyR1 by siRNA did not affect myotube differentiation; indeed 
mean myotube diameter as well as the relative expression of differentiation-related markers 
such as dystroglycan 1 (DAG), myosin heavy chain 1 (MHC1), troponin T1 (TNNT1) and 
desmin (DES) (Galbiati et al., 1999; Trendelenburg et al., 2009) were similar in control and 
RYR1 siRNA transfected myotubes (Fig. 4). 
 
RyR1 Deficiency Affects Cav1.1 Content 
We next assessed if the decrease in mRNA in siRNA transefcted immortalized cells 
was paralleled by a decrease in protein content. Fig. 5A shows a representative western blot 
performed seven days after treatment and Fig. 5B shows the mean (±SEM) protein content in 
control versus siRNA treated myotubes. As shown desmin and tubulin content were not 
affected by RYR1 siRNA but there was a >50% decrease in RyR1, Cav1.1, SERCA2 and α-
actinin content as assessed by western blotting in myotubes transfected with 50 nM RYR1 
siRNA. Unexpectedly, the relative content of IP3RIII, the other intracellular Ca2+ release 
channel of ER membranes was increased by approximately two-fold.  
The protein content of Cav1.1, SERCA2, α-actinin2 and IP3RIII were also assessed in 
the muscle biopsies from patients with RyR1 deficiency due to recessive mutations. Western 
blotting was performed on protein extracted from the muscle biopsies of two patients and 
three normal controls. The immunohistochemical staining of RyR1 and DHPR of patient 2 
was shown in Fig. 1; the double staining of RyR1 and DHPR in patient 5 has been previously 
reported (Zhou et al., 2010), with similar distribution pattern as shown in Fig. 1.  
Representative blots from patients and controls are shown in Fig. 5C. There was a 
significant reduction of both RyR1 and DHPR proteins in the samples from the patients 
compared to controls (N=3) (Fig. 5D). Significant up-regulation of IP3R III (approximately 
two-fold) was also observed in patients’ muscle biopsies compared to the controls (Fig. 5D). 
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However, no changes in SERCA2 and α–actinin 2 protein was observed in the patients’ 
muscle biopsies samples.   
 
All Three Types of ITPRs Transcripts Are Up-regulated in RYR1 Knockdown Myotubes 
and in Skeletal Muscles from Patients with Primary RyR1 Deficiency 
The transcripts of all three isoforms of Inositol-1,4,5- Triphosphate Receptor (IP3R) 
genes (ITPR1, ITPR2 and ITPR3) were quantified by real-time RT-PCR in myotubes treated 
by RYR1 siRNA. Significant up-regulation of all three isoforms of ITPRs was observed in the 
RYR1 knocked down group compared to the control group (Fig. 6A). We then analysed 
ITPRs transcripts in skeletal muscle from controls (N=7), from patients with dominant RYR1 
mutations (N=5) and from patients with heterozygous recessive RYR1 mutations and RyR1 
protein deficiency (N=6). To ensure that the observed alterations were not due to 
heterogeneous tissue composition of the biopsies due to variable degrees of fibrosis or 
connective tissue accumulation, we used both the ubiquitous housekeeping gene GAPDH and 
muscle specific DES gene as internal reference genes. Irrespective of whether the analysis 
was made using GAPDH (Fig. 6B) or DES (Fig. 6C), patients with recessive RYR1 mutations 
showed significant up-regulations of all three IP3R transcripts, compared to the control group. 
No significant differences in ITPR1, ITPR2 and ITP3R expression were observed between the 
group of patients harbouring dominant RYR1 mutations and the control group, except for a 
patient carrying the dominant mutation p.R4861C, who showed unusually high levels of 
ITPRs expression. Interestingly, though this mutation was identified as de novo and was not 
found in either parent, the case was initially considered a recessive core myopathy because of 
the severe clinical features of the patient and the abnormality observed in parent’s muscle 
biopsy (Manzur et al., 1998). Unfortunately the muscle biopsy failed western blotting RyR1 
protein quantification due to sampling problems. In order to rule out the presence of other 
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allelic mutations, we performed genomic analysis of the entire coding region and exon/intron 
boundaries of the RYR1 gene; no other pathogenic variants were identified in this patient 
suggesting that in this patient the p.R4861C mutation is responsible for the pathological 
phenotype. 
Taken together these results confirm that RyR1 deficiency induced in vitro as well as 
RyR1 protein deficiency occurring in vivo due to recessive RYR1 mutations cause the up-
regulation of ITPRs transcripts.  
 
Changes in Intracellular Ca2+ Homeostasis in RYR1 Knocked Down Myotubes 
Using the human muscle cell line we assessed how down regulation of RyR1 by 
siRNA affects calcium homeostasis. Besides the resting [Ca2+] and the size ionomycin 
sensitive Ca2+ stores, we measured several parameters, including the response (expressed as 
area under the curve, which more accurately reflects the total amount of Ca2+ released) of 
myotubes to KCl-induced depolarization, to pharmacological activation of RyR1 with 4-
chloro-m-cresol and to ATP stimulation (which measures Ca2+ release via IP3R) in control 
cells, control cells treated with the IP3R inhibitor Xestospongin C and in RYR1 siRNA 
treated cells (± Xestospongin C). This approach allows us to evaluate if the decrease in Ca2+ 
released due to downregulation of RyR1 could be compensated by up-regulation of IP3R-
mediated Ca2+ release.  Fig. 7 shows that RyR1 activation either directly by the addition of 
600 µM 4-chloro-m-cresol or indirectly, by the addition of 60 mM KCl induces a large Ca2+ 
release that is independent of IP3Rs since the same amount of Ca2+ was released whether 
cells had been pre-treated or not with Xestospongin C. Downregulation of RYR1 by 50 nM 
siRNA caused a 3 -fold decrease of Ca2+ release by 4-cmc and KCl that was unaffected by 
Xestospongin C. Addition of 100 µM ATP (i) caused the release of approximately 50% of the 
Ca2+ compared to the release obtained by RyR1 activation, (ii) was inhibited by Xestospongin 
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C and importantly, (iii) was unaffected by down-regulation of RYR1.  Downregulation of 
RyR1 affected neither the resting [Ca2+] nor the total amount of ionomycin-induced Ca2+-
release, indicating no significant effect on the size of the intracellular Ca2+ stores. These 
results indicate that upregulation of IP3R does not functionally compensate the decreased 
Ca2+-release due to the lower levels of RyR1 protein content. 
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Discussion 
RYR1-related disorders with mainly dominant inheritance and normal RyR1 protein 
expression have been extensively studied at the functional level, whereas the mechanisms 
underlying RYR1-related myopathies with recessive inheritance and RyR1 deficiency remain 
only partially understood. Functional studies of common dominant RYR1 mutations 
associated with CCD indicate two principal mechanisms associated with disturbed function 
of the mutant RyR1 channel, namely presence of a  ‘leaky channels’ associated with 
reduction of SR calcium  stores (Lynch et al., 1999), or “uncoupled” channels with muscle 
weakness resulting from a reduced capacity of RyR1 to transport Ca2 (Avila et al., 2001). In 
the present study, we report that recessive RYR1 mutations associated with RyR1 deficiency 
are also responsible for E-C uncoupling by negatively affecting DHPR-RyR1 co-localization 
in skeletal muscle. Indeed, this kind of E-C uncoupling was initially reported in two animal 
models of RYR1-related disorders, the sporadic zebrafish relatively relaxed mutant with 
marked reduction of functional RyR1 protein (Hirata et al., 2007), and in Ryr1 knockout 
(dyspedic) mice which do not express any ryanodine receptor 1 (Takeshima et al., 1994). In 
dyspedic myotubes cultured from Ryr1 knockout mice there is no E-C coupling, whereas 
introduction of exogenous RyR1 restores E-C coupling and increases the density of the L-
type Ca2+ current towards normal (Nakai et al., 1996). The dependence of physiological E-C 
coupling on correct mechanical coupling is also indicated by ultrastructural studies 
demonstrating the importance of a tight alignment of RyR tetramers on the junctional face 
membrane and of DHPR molecules (a tetrad) on the opposing T-tubule membrane (Block et 
al., 1988). 
Interestingly, depletion of RyR1 in vitro by siRNA in an immortalized human muscle 
cell line caused a decrease of Cav1.1 content, suggesting that proper alignment between the 
two calcium channels is required for the stability of the complex. Diminishment of Cav1.1 
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content has also been reported in dyspedic mouse skeletal muscle (Buck et al., 1997) and in 
one previous immunohistochemical study on core myopathies, in which a patient exhibiting 
virtual absence of RyR1 showed focal accumulation of DHPR within or around the cores 
(Herasse et al., 2007). The loss of DHPR/RyR1 co-localization strongly suggests a physical 
E-C uncoupling in patients with some recessive RYR1 mutations. We suggest that the 
characteristic staining pattern of Cav1.1 may be a useful immunohistochemical indicator to 
select patients for RYR1 sequencing, currently still very costly and time consuming due to the 
large size of the gene.  
Aside the down-regulation of Cav1.1, we observed down-regulation of SERCA2 and 
alfa-actinin in RyR1 knocked-down myotubes. This is in contrast to the up-regulation of 
SERCA reported in dyspedic myotubes (Eltit et al., 2010; Eltit et al., 2011) and to the lack of 
changes in SERCA2 and alfa-actinin protein levels in the patient’s biopsies. Opposing effects 
on SERCA2 expression have been reported in C2C12 cells transfected with two different 
RYR1 mutations. Vega et al. (Vega et al., 2011) reported that transfection with the RYR1 
Y523S MH-linked mutation caused an increase in SERCA2 expression whereas transfection 
of C2C12 cells with the CCD-linked I4897T RYR1 mutation caused its down-regulation. 
Furthermore they also reported that the expression of a particular mutant affects the degree of 
myotube differentiation, in that C2C12 cells transfected with the RyR1 cDNA harbouring the 
I4897T mutation were similar to control myotubes in size and fusion index 8 days after 
differentiation, while cells transfected with the RyR1 cDNA harbouring the Y523S 
substitution were larger than control myotubes (Vega et al., 2011). We did not find any 
significant differences in size and in the expression of differentiation-related markers such as 
dystroglycan 1, troponin T1, myosin heavy chain and desmin (Galbiati et al., 1999; 
Trendelenburg et al., 2009) in RYR1siRNA transfected and control cells. Thus knocking 
down a protein in vitro does not mimic all aspects of what happens in vivo in muscles of 
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patients harbouring recessive mutations causing RyR1 depletion and further experiments are 
required to understand the mechanisms involved in the reciprocal regulation of SR proteins.  
 In the present study we demonstrate that in human skeletal muscle under conditions of 
RyR1 deficiency, IP3R are up-regulated. In cultured mouse skeletal muscle cells IP3R are 
predominantly expressed around the nuclear envelope, are mainly associated with slow Ca2+ 
transients and appear to be involved in the regulation of gene expression (Jaimovich et al., 
2000; Jaimovich and Carrasco, 2002). The IP3/IP3R-induced calcium signal plays little or no 
substantial role in skeletal muscle E-C coupling under physiological conditions (Posterino 
and Lamb, 1998) and as shown in the present study, up-regulation of IP3R in RyR1–deficient 
states does not compensate for the physical collapse of the E-C coupling machinery. 
Nevertheless, the IP3/IP3R pathway may be involved in slow calcium release leading to 
activation of expression of certain genes and the present study indicates the possible 
existence of a complex interplay RyR1 and IP3R signalling pathways.  
In conclusion, our results demonstrate up-regulation of an alternative calcium 
regulating system via IP3R in recessive RYR1-related myopathies with RyR1 deficiency, and 
indicate the potential importance of the IP3R signalling cascade in the pathophysiology of 
these neuromuscular disorders. Future studies aimed at determining the role of the IP3R 
system in RyR1 deficient congenital myopathies and its correlation with disease progression 
could provide further insight into the pathogenesis of this condition.  
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Figure 1: Protein expression of RyR1 and DHPR in muscle biopsy of patients with 
different RYR1 mutations.  Double staining of RyR1 and DHPR, and NADH staining in 
muscle biopsies of patients with congenital myopathy and RYR1 mutations. NADH staining 
was performed in non-serial sections from RyR1/DHPR double staining. Scale bar = 25µm. 
 Figure 2: Quantitative reverse transcriptional real-time PCR of RYR1 and 
CACNA1S in skeletal muscle biopsies from patients carrying different RYR1 mutations. 
 The relative content of RYR1 and CACNA1S mRNA was assessed by real-time PCR 
using ∆∆Ct method and using DES as muscle specific reference gene. The relative expression 
of RYR1 and CACNA1S to DES in one of the control individuals was set as 1.0, and was used 
to calibrate the values of all other samples. Each symbol represents an individual and the bar 
indicates mean relative expression. ANOVA was used for the statistical analysis of the values 
in different groups, followed by the Bonferroni post statistics test. A) Relative expression of 
RYR1 transcript in muscle biopsies. B) Relative expression of CACNA1S transcript in muscle 
biopsies. * P<0.05, ** P<0.01.   
Figure 3: RYR1, CACNA1S and DES mRNA expression in myotubes treated with RYR1 
siRNA.  The relative quantification of RYR1 (A), CACNA1S (B) and DES (C) mRNA 
was performed   by quantitative real-time PCR. The value was obtained from three 
independent transfection experiments of myotubes treated with RYR1 siRNA at 
concentrations of 10 nM, 30 nM and 50 nM. The data is presented as Mean ± SEM, N=3. 
ANOVA was used for the statistical analysis of the values in the RYR1 siRNA treated 
myotubes to negative control siRNA, followed by Bonferroni post statistics test. The relative 
expression of target genes in control siRNA treated myotubes was set as 1.0, and was used to 
normalize the values in the RYR1 siRNA treated myotubes. * P<0.05, ** P<0.01.  
Figure 4: Down-regulation of RyR1 by RYR1 siRNA transfection does not affect 
myotube differentiation: Cells were transfected with 50 nM RYR1 siRNA, differentiated for 
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5 days and then stained with β-tubulin and DAPI, the diameter of myotubes with >3 nuclei 
were measured and averagedconsidered. (A). Mean (±SE) myotube diameter (µm) of 30 
transfected and 30 mock transfected myotubes. (B). Relative mRNA expression of 
differentiation-related markers; Dystroglycan 1 (DAG), Myosin heavy chain 1 (MYH1), 
Troponin T1 (TNNT1) and Desmin (DES) normalized to GAPDH expression as internal 
control (N=6). (C). Immunofluorescentce of transfected (RYR1siRNA) or mock transfected 
(control) myotubes stained with anti- β tubulin (green) and DAPI and observed with a Nikon 
A1R confocal microscope with a 40X NeoFluar objective (1.4 NA). Bar indicates 30 µm. 
Figure 5: RyR1, DHPR and other SR protein in RYR1 siRNA treated myotubes and 
muscle biopsies from patients with RyR1 deficiency due to recessive RYR1 mutations 
A) Representative western blots of RyR1, DHPR, IP3R-III, α-actinin 2, SERCA 2, desmin 
and β-tubulin in human myotubes treated by RYR1 siRNA. B) Semi-quantification of proteins 
in RYR1 siRNA treated myotubes. The expression of proteins was normalized to tubulin. 
Protein content in RYR1 siRNA treated group was compared to the control group. C) 
Representative western blots of RyR1, DHPR, IP3R-III, α-actinin 2, SERCA 2, and desmin 
in muscle biopsies from 2 patients (patient 2 and 5 in Table 1) with recessive RYR1 
mutations. D) Semi-quantification of proteins in two patients, with RyR1 deficiency due to 
recessive RYR1 mutations, and three controls. The expression of proteins was normalized by 
desmin. 
Figure 6: The expression of ITPR1, ITPR2 and ITPR3 mRNA in RYR1 siRNA treated 
myotubes and skeletal muscle biopsies from patients with different RYR1 mutations. A) 
The relative expression of ITPRs mRNA in cultured myotubes treated with siRNA was 
measured by quantitative reverse transcript real-time PCR. Data is presented as Mean±SEM. 
N=4 samples per group. * P<0.05. B) The relative expression of ITPRs mRNA measured by 
quantitative real-time PCR in skeletal muscle biopsies from controls (N=7), patients with 
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dominant RYR1 mutations (N=5) and patients with complex recessive RYR1 mutations with 
RyR1 protein deficiency (N=6). GAPDH was used as general internal control gene. C) The 
relative expression of ITPRs mRNA measured by quantitative real-time PCR in skeletal 
muscle biopsies by using DES as muscle-specific internal control gene.  
Figure 7: Analysis of calcium regulation in a human muscle cell line after transfection 
with RYR1 siRNA. Cells were transfected with 50 nM RYR1 siRNA or mock transfected as 
described in the Methods section and were either untreated or treated with 1 µM 
Xestospongin C during the 40 minutes of fura-2 loading. Myotubes were stimulated with the 
indicated agonist in Krebs-Ringer containing no added Ca2+ plus 100 µM La3+ and the total 
amount of calcium released was calculated using Origin software by calculating the total 
transient, i.e. the area under the curve. Resting [Ca2+] is presented as fluorescence ratio 
(340/380 nm)(au) before cell stimulation in Krebs-Ringer containing 2 mM Ca2+; the total 
amount of rapidly releasable Ca2+ present in the SR/ER stores was obtained by calculating the 
area under the curve after exposing cells to 1 µM ionomycin in the Krebs-Ringer containing 
no added Ca2+ plus 0.5 mM EGTA. For details see Methods section. All results are expressed 
as mean value (±SEM) of the indicated number of cells. White bars mock transfected cells, 
grey bars cells transfected with RYR1 siRNA. Statistical analysis was performed using 
Student’s t-test.    
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